The TBCRC023 study explored the efficacy of lapatinib plus trastuzumab with letrozole for 12 weeks or 24 weeks in patients with ER‐positive, HER2‐positive breast cancer.33 The gene discussed is ERBB2; the disease is breast carcinoma.